For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

For Immediate Release: September 13, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA reissued the Aug. 19, 2022, letter of authorization for Novavax COVID-19 Vaccine, Adjuvanted to revise the conditions of authorization related to the Vaccine Adverse Event Reporting System (VAERS) reporting requirements for vaccination pr

For Immediate Release: July 13, 2022 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.  “Authorizing an additional COVID-19 vaccine expands the available vaccine options for the preventi

GAITHERSBURG, Md., May 7, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 14, 2025 Time: 3:00 – 3:30 p.m. Pacific Time (PT) Location: Las Vegas, NV Conference Event: Investor Meetings Date: Wednesday, May 14, 2025 A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days. About NovavaxNovavax, Inc. (NASDAQ:NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines

Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will continue to be available in Japan, the world's third largest pharmaceutical marketGAITHERSBURG, Md., May 5, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regu

GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows: Conference call details: Date: May 8, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/43UHjFq Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants

GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp

Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccineFull results will be submitted for publication later this yearGAITHERSBURG, Md., April 15, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced preliminary results from the SHIELD-Utah study (Study of Healthcare Workers and First Responders Investigating Effects of Systemic and Local reactogenicity of COVID-19 Vaccine Doses in Utah) that showed Novavax's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) targeting the JN.1 strain resulted in fewer and less severe reactogenicity symptoms, w

James Young, PhD retires as Chair of the Board, Margaret McGlynn, RPh, appointedJohn Shiver, PhD appointed to board of directorsGAITHERSBURG, Md., March 11, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed John Shiver, PhD, to its board as an independent director. Dr. Young made the decision to resign from the board effective March 10, 2025. He has served on Novavax's board since 2010 and as Chair since 2011. During

GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), today announced that the management team will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference: Fireside Chat Date: Tuesday, March 4, 2025 Time: 9:10 – 9:40 a.m. Eastern Time (ET) Location: Boston, MA   Conference Event: Investor Meetings Date: Tuesday, March 4, 2025 Leerink Partners 2025 Global Healthcare Conference: Presentation Date: Tuesday, March 11, 2025 Time: 3:40 – 4:10 p.m. ET Location: Miami Beach, FL   Conference Event: Investor Meetings Date: Tuesday, March 11, 2025 Jefferies Biotech on the Beach Summit: Conference Event: Investor Meetings Date: Wed

Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohortCompleted $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 millionAdvanced pipeline programs, based on proven and innovative technology platformEnded full year 2024 with over $1 billion in Cash and accounts receivablesProvides 2025 financial guidance and revenue framew

GAITHERSBURG, Md., Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 27, 2025. Details of the event and replay are as follows: Conference call details: Date: February 27, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3PsP11e Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast:   ir.novavax.com/events Participants can join the conference call without operator assistance by regist

Capstone Companies, Inc. (OTCQB:CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025. Mr. Rosen has extensive experience in marketing, business development, contract negotiation and government relations as well as experience as a member of two public companies' management. He served as Senior Vice President, Global Market Access, Public Policy & Alliances (2021 - 2023), Senior Vice President, Commercial Strategy (2018 - 2021) and Vice President, Market Access, Policy, & Government Affairs (2015 - 2017) with Novavax, Inc. (NASDAQ:NVAX). Before Novavax, Inc., Mr. Rosen served as Chief Policy, Advocacy & Patient Services Officer (2014 -

8-K - NOVAVAX INC (0001000694) (Filer)

DEFA14A - NOVAVAX INC (0001000694) (Filer)

DEF 14A - NOVAVAX INC (0001000694) (Filer)

8-K - NOVAVAX INC (0001000694) (Filer)

8-K - NOVAVAX INC (0001000694) (Filer)

8-K - NOVAVAX INC (0001000694) (Filer)

8-K - NOVAVAX INC (0001000694) (Filer)

8-K - NOVAVAX INC (0001000694) (Filer)

8-K - NOVAVAX INC (0001000694) (Filer)

8-K - NOVAVAX INC (0001000694) (Filer)

GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp

Capstone Companies, Inc. (OTCQB:CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025. Mr. Rosen has extensive experience in marketing, business development, contract negotiation and government relations as well as experience as a member of two public companies' management. He served as Senior Vice President, Global Market Access, Public Policy & Alliances (2021 - 2023), Senior Vice President, Commercial Strategy (2018 - 2021) and Vice President, Market Access, Policy, & Government Affairs (2015 - 2017) with Novavax, Inc. (NASDAQ:NVAX). Before Novavax, Inc., Mr. Rosen served as Chief Policy, Advocacy & Patient Services Officer (2014 -

Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organizationDr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platformGAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in November 2024 as Executive Vice President and Head of Research & Development (R&D). Dr. Draghia-Akli brings m

Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price       Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management's failure to capitalize on Novavax's many significant competitive advantages and TAM opportunities The letter highlights that the underperformance is self-inflicted and is the result of reactive leadership and outdated and old-fashioned marketing RALEIGH, N.C., April 15, 2024 (GLOBE NEWSWIRE) -- Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax (NASDAQ:NVAX), ha

New organizational structure for executive leadership team designed to facilitate a leaner and more focused approach to annual execution of business plansJohn Trizzino appointed to new Chief Operating Officer roleMark Casey to join as Chief Legal Officer and Corporate SecretaryGAITHERSBURG, Md., Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week. John Trizzino will take on the newly created role of President and Ch

Current President & CEO Stanley C. Erck will retire effective January 23 with plans to support the leadership transition in an advisory capacity Novavax is well-positioned to execute on its strategy, with global authorizations for its COVID-19 vaccine and continued clinical pipeline developmentGAITHERSBURG, Md., Jan. 9, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John C. Jacobs will succeed Stanley C. Erck as President and Chief Executive Officer and a member of the Board of Directors. The transition will be effective as of January 23, 2023.

GAITHERSBURG, Md., Nov. 1, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of Richard Rodgers, MBA to its board as an independent director. Mr. Rodgers brings extensive experience in biopharmaceutical management to his role on the Novavax Board of Directors. "Rick's deep experience in the pharmaceutical industry coupled with his extensive acumen in building rapidly growing companies and financial leadership will be invaluable as we continue the commercialization of our COVID-19 vaccine and expand our vaccine pipeline," said Stanley C.

REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serves as the Chief Executive Officer of National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, which he co-founded and built, with end-to-end manufacturing and digital s

GAITHERSBURG, Md., Aug. 16, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, and Nasir Egal, Ph.D. as Senior Vice President, Quality Assurance. Mr. Kelly will report to Stanley C. Erck, President and Chief Executive Officer, and Dr. Egal will report to Rick Crowley, Executive Vice President and Chief Operations Officer. Mr. Kelly brings more than twenty-five years of industry experience in both commercial and clinical-stage companies to Novavax. He joins Novavax from Supernus Pharma

GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ --  Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief Scientist, and the appointment of Troy Morgan as Senior Vice President, Chief Compliance Officer. The company also announced that Greg Covino will be stepping down as Chief Financial Officer (CFO) and will take on a new role as executive adviser to the company. Recognized as a pioneer in vaccine research, Dr. Smith is the senior inventor of the insect cell technology that serves as the basis of N

BTIG Research initiated coverage of Novavax with a rating of Buy and set a new price target of $19.00

JP Morgan downgraded Novavax from Neutral to Underweight and set a new price target of $8.00

BofA Securities upgraded Novavax from Underperform to Neutral and set a new price target of $12.00 from $4.00 previously

JP Morgan upgraded Novavax from Underweight to Neutral

B. Riley Securities upgraded Novavax from Neutral to Buy and set a new price target of $15.00

TD Cowen downgraded Novavax from Outperform to Market Perform and set a new price target of $10.00 from $55.00 previously

B. Riley Securities downgraded Novavax from Buy to Neutral and set a new price target of $10.00 from $29.00 previously

B. Riley Securities reiterated coverage of Novavax with a rating of Buy and set a new price target of $37.00 from $74.00 previously

H.C. Wainwright reiterated coverage of Novavax with a rating of Buy and set a new price target of $110.00 from $207.00 previously

Jefferies initiated coverage of Novavax with a rating of Hold

4 - NOVAVAX INC (0001000694) (Issuer)

3 - NOVAVAX INC (0001000694) (Issuer)

4 - NOVAVAX INC (0001000694) (Issuer)

3 - NOVAVAX INC (0001000694) (Issuer)

4 - NOVAVAX INC (0001000694) (Issuer)

4 - NOVAVAX INC (0001000694) (Issuer)

4 - NOVAVAX INC (0001000694) (Issuer)

4 - NOVAVAX INC (0001000694) (Issuer)

4 - NOVAVAX INC (0001000694) (Issuer)

4 - NOVAVAX INC (0001000694) (Issuer)